Keros Therapeutics (KROS) Non Operating Income (2019 - 2025)

Keros Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $4.3 million for Q4 2025.

• Quarterly Non Operating Income fell 42.95% year-over-year to $4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.3 million (up 2.3% YoY) and the FY2025 annual result came in at $24.3 million, up 2.3% from the prior year.
• Non Operating Income was $4.3 million for Q4 2025 at Keros Therapeutics, down from $6.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $7.5 million in Q4 2024 and bottomed at -$138000.0 in Q3 2021.
• A 5-year average of $3.7 million and a median of $4.1 million in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2021 — Non Operating Income sank 151.59% — and 2023, when it surged 5208.33%.
• Keros Therapeutics' Non Operating Income stood at -$75000.0 in 2021, then soared by 3089.33% to $2.2 million in 2022, then jumped by 177.07% to $6.2 million in 2023, then gained by 21.18% to $7.5 million in 2024, then slumped by 42.95% to $4.3 million in 2025.
• Business Quant data shows KROS's Non Operating Income at $4.3 million in Q4 2025, $6.7 million in Q3 2025, and $6.9 million in Q2 2025.